Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German state streamlines clinics to target breast cancer

This article was originally published in Clinica

Executive Summary

The German federal state of North Rhine-Westphalia (NRW) has made a decisive move towards improving the care of breast cancer patients, by restricting treatment to specialist breast cancer clinics. As a result, only hospitals which carry out at least 150 breast cancer operations on new patients annually, or at least 100 repeat procedures, and have specialists who personally carry out at least 50 operations per year will be allowed to carry out breast cancer treatment. Hospital departments that fail to fulfil these requirements will either be closed down, or forced to merge with those that do. This would see the number of hospitals carrying out such operations fall from 250 to only 50, with each specialist centre caring for between 360,000-450,000 women.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT067619

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel